Mounjaro (tirzepatid) – price, side effects and dosage in Sweden

01 Mar

Mounjaro has in a short time become one of the most sought-after drugs for weight loss in Sweden and the rest of Europe. The preparation, which is based on the active substance tirzepatide, was approved by the EMA for the treatment of type 2 diabetes and obesity — and the results of clinical trials exceeded most we had seen before. In this article, we go over how Mounjaro works, what it costs, what side effects can occur and what results you can realistically expect.

How Mounjaro and tirzepatid work in the body

Tirzepatid differs from older weight loss drugs by activating two receptors simultaneously: GLP-1 and GIP. Most competing drugs — for example, semaglutide (Ozempic, Wegovy) — only stimulate the GLP-1 receptor. The dual mechanism of action gives Mounjaro a wider grasp of the body’s metabolism.

GLP-1 and GIP — what do they actually do?

GLP-1 (glucagon-like peptide-1) slows gastric emptying, reduces appetite and helps the pancreas to release more insulin with meals. GIP (glucose-dependent insulinotropic polypeptide) enhances this effect and also affects the metabolism of adipose tissue. Together, they lower blood sugar more stably and suppress hunger more effectively than a single receptor can handle.

In practice, this means that most users experience a significantly reduced appetite already during the first weeks. The feeling of satiety occurs more quickly during meals, and “cravings” after snacks are reduced. This combination makes tirzepatide one of the most potent substances in modern weight loss treatment.

Mounjaro dosage — escalation schedule week by week

Treatment always begins with a low dose that is gradually increased. The purpose is to give the body time to get used to the substance and minimize side effects, especially nausea.

|Week|Dose|Purpose|

|Weeks 1–4|2.5 mg/week|Starting dose — the body adapts|

|Weeks 5–8|5 mg/week|First effective maintenance dose|

|Week 9–12|7.5 mg/week|Possible increase if necessary|

|Week 13–16|10 mg/week|Intermediate dose for additional effect|

|Week 17+|12.5–15 mg/week|Maximum dose in case of insufficient results|

Each dose is injected subcutaneously once a week — in the abdomen, thigh, or upper arm. We recommend rotating the injection site between doses to avoid local irritation. The injection only takes a few seconds and the pre-filled pens do not require any special technical knowledge.

Many people stop at 5 mg or 10 mg a week if the results are satisfactory. Increasing the dose unnecessarily increases the risk of side effects without proportional improvement in weight loss. The clinical rule of thumb: if you are still losing weight at a steady rate on your current dose, there is no reason to escalate the dose.

Mounjaro side effects — what you can expect

Like all GLP-1-based drugs, Mounjaro comes with a range of potential side effects. The most common ones are connected to the gastrointestinal tract and occur mainly during the first weeks or when the dose is increased.

Common side effects in clinical trials

Nausea is the most commonly reported side effect — approximately 20-25% of participants in the Phase 3 studies experienced it to some degree. Diarrhea and constipation affect 10-15% and often resolve within two to three weeks. Decreased appetite is technically classified as a side effect, but for many users is exactly the effect they are looking for.

More serious but rare side effects include inflammation of the pancreas (pancreatitis), gallbladder problems and, in very rare cases, allergic reactions. The risk of hypoglycaemia (too low blood sugar) is low if you are not taking sulphonylureas or insulin at the same time. Animal studies have shown a link to thyroid tumors — but it’s unclear if this applies to humans. People with a personal or family history of medullary thyroid cancer are advised against treatment.

Do you experience severe nausea during the escalation? Stay on your current dose for an extra week before increasing. It significantly reduces discomfort for most people. Avoid large, fatty meals — instead, eat smaller portions and drink water regularly. Some users report that the nausea almost completely disappears after 6-8 weeks on a stable dose.

Mounjaro results — how much weight can you lose?

The results from the SURMOUNT studies provide a clear picture. In SURMOUNT-1, participants without diabetes lost an average of 22.5% of their body weight on the 15 mg dose after 72 weeks. This corresponds to approximately 24 kg for a person who weighs 105 kg at the start.

Even the lowest effective dose (5 mg) produced impressive numbers — around 15% weight loss over the same period. In comparison, semaglutide (Wegovy) is about 15-16% weight loss at optimal dose, making tirzepatide the most effective substance in its class.

• Average weight loss at 5 mg: ~15% of body weight

• Average weight loss at 10 mg: ~19.5% of body weight

• Average weight loss at 15 mg: ~22.5% of body weight

• Proportion of participants who achieved >20% weight loss at 15 mg: 63%

Results will of course vary individually. Physical activity level, dietary habits, starting BMI and genetic factors influence the outcome. People with higher starting weights tend to lose more in absolute terms, while percentage figures are more comparable. But the pattern from the trials is clear: most people lose a significant percentage of their body weight. Weight loss is greatest during the first 40 weeks and then levels off, indicating that the body is reaching a new equilibrium point.

Mounjaro price in Sweden — how much does the treatment cost?

The price issue is central to anyone considering Mounjaro. In Sweden, the preparation is subsidized via the Dental Care and Medicines Benefit Agency (TLV) for patients with type 2 diabetes who meet specific criteria. For weight loss without a diabetes diagnosis, it falls outside the benefit system, which means that you pay the entire cost yourself.

The price varies depending on the dose and method of purchase. A pre-filled injection pen with a dose of 5 mg currently costs (2026) approximately SEK 1,300–1,600 per pen through Swedish pharmacies — provided you have a prescription and diabetes indication. Without subsidy, the monthly cost rises to SEK 4,000–6,000 depending on the dose.

For those looking for tirzepatide as research peptide the prices are considerably lower. Pure peptide preparations in bottle format cost a fraction compared to ready-made injection pens, but require their own preparation and dosing. This route is often chosen by experienced users who want control over dosage and cost.

Mounjaro before and after — realistic expectations

We often see before-and-after pictures circulating on social media, and there is a risk that expectations are turned up unrealistically high. The truth is that most people lose 15-22% of their body weight in the first year — not 40 or 50 kg in three months.

The first four weeks on the starting dose (2.5 mg) are mostly about adapting the body. Weight loss during this period is modest — often 1–2 kg. From week 5 onwards, when the dose is increased to 5 mg, the process accelerates. Most people report their most intense weight loss between week 8 and week 40.

One factor rarely discussed: Mounjaro tends to preserve muscle mass better than extreme calorie restriction. In the SURMOUNT studies, approximately 70% of the weight lost was from adipose tissue, which is a better ratio than in traditional low-calorie diets. Combining the treatment with strength training improves this further. Without training, you risk losing muscle, which then takes a long time to build up again.

Should you end the treatment? Plan a gradual taper. Studies show that a large percentage of the lost weight is regained within 12 months of the end of treatment unless diet and exercise habits have been changed permanently. Tirzepatid is not a substitute for a sustainable lifestyle — but it can be the tool that makes the lifestyle change possible.

.entry-content